Defiance Daily Target 2X Long AVGO ETF (NASDAQ: AVGX)

에 대한 최신 뉴스 Defiance Daily Target 2X Long AVGO ETF (NASDAQ:AVGX)

Defiance Daily Target 2X Long AVGO ETF

Healthcare

The Fund is an actively managed exchange traded fund (ETF) that attempts to achieve two times (200 percent) the daily percentage change in the share price of the Underlying Security by entering into swap agreements on the Underlying Security. The Fund aims to achieve this daily percentage change for a single day, and not for any other period. A single day means the period from the close of regular trading on one trading day to the close on the next trading day.

First American Government Obligations Fund

Broadcom Inc

Eli Lilly & Co.

News

Contracts

HII Among Companies Included On Multiple Award Live Training Contract For US Army; Contract Ceiling $379M

<a href="https://www.globenewswire.com/Tracker?data=a5qZALx-iMXMFoZfPTaJidhpm8k3nR7hkMQfdG8tw-PH00Wrcg4-P0pObXWrcwEEyXXJgVb0IMOuS1l89zgcQptN253Mx1Qn9YzQP1IrhVw=">Genius Group Limited</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that further to the favorable ruling by the U.S. Court of Appeals on May 6, 2025, allowing Genius Group to resume buying Bitcoin, the Company has increased its Bitcoin Treasury by 52% to 100 Bitcoin.
Over the last month, the Company has increased its Bitcoin Treasury by an additional 52%, with the purchase of 34 Bitcoin. The Company currently holds 100 Bitcoin purchased for $10.06 million, at an average price of $100,600 per Bitcoin.
The Company maintains its target to build its Treasury to 1,000 Bitcoin.

Genius Group Increases Bitcoin Treasury By 52% To 100 Bitcoin

<ul>
<li>Acquisition Target Specializes in Precision Milling, Turning, Mold Manufacturing, and Specialty Metals Expertise Serving Aerospace, Defense, and Industrial Markets</li>
<li>This is PMGC's third pending acquisition since April of 2025, demonstrating that its M&amp;A strategy is well underway, with additional deals expected&nbsp;this&nbsp;year.</li>
<li>PMGC Sees Significant Opportunity in Acquiring Additional US based CNC and Precision Manufacturing Companies Serving Aerospace, Industrial, and Defense&nbsp;Markets. &nbsp;</li>
</ul>
NEWPORT BEACH, Calif., June 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent ("LOI") to acquire a California-based, cash-flow positive computer numerical control ("CNC") machining company with over 35 years of operational history.

ELAB

PMGC Holdings Signs Non-Binding LOI To Acquire California-Based Computer Numerical Control Machining Company; Terms Undisclosed

Citigroup analyst Ronald Josey initiates coverage on MNTN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNTN#NYSE">MNTN</a>) with a Neutral rating and announces Price Target of $22.

Price Target

Initiation

Analyst Ratings

MNTN

Citigroup Initiates Coverage On MNTN with Neutral Rating, Announces Price Target of $22

AIMD

Ainos Says VELDONA Oral Interferon Received Approval To Begin Human Trials In Taiwan

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16085917/SICC-0616-900x600-1.png" alt="" class="wp-image-14433" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16085917/SICC-0616-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16085917/SICC-0616-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16085917/SICC-0616-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The maker of silicon carbide substrates has been cleared by China's securities regulator to list in Hong Kong, even as its revenue began to contract in the first quarter
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>The Chinese securities regulator has registered an IPO plan by semiconductor firm SICC, clearing the way for its listing to proceed in Hong Kong</li>
<li>After reporting strong revenue gains in 2023, the SiC substrate maker's growth slowed sharply last year and began to contract in the first quarter of 2025</li>
</ul>
What a difference four months makes.
When semiconductor company&nbsp;SICC Co. Ltd.&nbsp;(688234.SH) first filed to list in Hong Kong back in February, it was boasting strong double-digit revenue growth and was on track to report its first annual profit. The company's Hong Kong listing, which was just approved by China's securities regulator on Friday, would complement its existing listing on Shanghai's STAR Market.
The listing plan's&nbsp;<a href="http://www.csrc.gov.cn/csrc/c105984/c7564412/content.shtml">registration</a>&nbsp;by the China Securities Regulatory Commission (CSRC) officially clears the way for SICC to sell shares into one of the hottest Hong Kong IPO markets in years. It plans to sell 87.2 million shares in the listing, according to the CSRC registration statement.
The listing is being underwritten by two of China's largest investment banks, CICC and Citic Securities, indicating it will mostly target Asian investors. That's not too surprising, since the West – and the U.S. in particular – are increasingly taking steps to ban their investors from buying shares in Chinese makers of cutting-edge technologies, including microchips that are used in many high-tech gadgets, but also have defense applications.
SICC's Hong Kong listing plan looked relatively attractive when it first filed its application in February, and&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107138/documents/sehk25022400646.pdf">updated the application</a>&nbsp;a month later. But since that application, which only included its financial information through the end of last September, its business has headed into a tailspin.
The company and its peers are being pummeled on a couple of fronts. SICC makes silicon carbide (SiC) substrates, which are the foundation used to make wafers that are ultimately carved into microchips. SICC's chips are used by a wide range of industries, but two of the biggest are the solar power equipment and new energy vehicle (NEV) makers.
In a situation that's all too common, SICC and its peers have built up huge capacity in the last few years to feed the booming solar energy and NEV sectors. That has resulted in overcapacity that is quite common in cutting-edge Chinese industries these days, undermining prices for the SiC substrates that account for more than 80% of SICC's sales.
Similar overcapacity in the NEV and solar power sectors is the other factor that's causing major headaches for SICC and its peers.
After posting strong double- and even triple-digit sales gains for the last two years, Chinese NEV manufacturers are suddenly seeing their growth slow sharply as the domestic market becomes saturated and foreign markets erect trade barriers to Chinese imports. The resulting price wars have caused NEV makers' losses to widen, making them pressure their suppliers for lower prices. The situation is similar for solar panel makers, many of which have slipped into the red as their production costs exceed tanking panel prices.
The price pressure was already evident in SICC's March listing application, though the effects appear to have worsened since then. The company said the average price for each of its SiC substrates was 4,185 yuan ($583) in the first nine months of last year, down from 4,798 yuan for all of 2023 and nearly 20% lower than 5,110 yuan it was getting in 2022. But its cost of sales have continued to climb steadily, growing 34% from 710 million yuan in the first nine months of 2023 to 954 million yuan in the same period of last year.
<h4 class="wp-block-heading">Revenue slips into contraction</h4>
SICC's original IPO application looked quite attractive, showing the company's revenue tripled in 2023 from the previous year as demand from the NEV and solar sectors boomed, and the company began mass production of its latest 8-inch substrates. Founded in 2010, SICC started out making 2-inch substrates, and added 4-inch and 6-inch products in 2015 and 2021, respectively. The larger a substrate, the higher its yield of microchips.
The company said it developed its first 12-inch SiC substrates last year, though those products have yet to go into mass production.
SICC wasn't the only company rolling out new products and boosting capacity, even as two of its largest customer groups were starting to show signs of distress last year. As those things happened, the company's growth slowed sharply in 2024, though it still looked respectable as its revenue rose 55% year-on-year in the nine months through September to 1.28 billion yuan.
That slowdown accelerated in last year's fourth quarter, as the company's revenue growth fell to just 14.3%, according to calculations using data from the listing document and full-year data from SICC's filings to the Shanghai Stock Exchange. That trend worsened in the first quarter of this year, as the company's revenue fell 4.25% to 408 million yuan from 426 million yuan a year earlier, according to its first-quarter report filed to the Shanghai Stock Exchange.
The company's margins and profits have followed similar trajectories. Its gross margin turned positive in 2023 at 14.6%, and rose further to 25.5% in the first nine months of last year. Similarly, it climbed out of the red by posting a 143 million yuan profit in the first nine months of last year, compared with a 68.2 million yuan loss in the year-ago period. But the company's profit plunged 82% to 8.52 million yuan in the first quarter of this year from 46.1 million a year earlier, suggesting it could slip back into the red later this year.
SICC said increased R&amp;D spending was partly behind the profit plunge, and, indeed, such spending rose to 11% of revenue in this year's first quarter from 5.2% a year earlier.
SICC's stock hasn't been a stellar performer since its Shanghai listing in 2022. The shares briefly traded nearly 50% higher than their IPO price shortly after the listing, but have given back all those gains and more since then. They now trade about 30% below their IPO price, following a selloff after it announced the worrisome first-quarter results.
Its less-than-stellar results are unlikely to excite investors, especially as SICC competes with a number of other similar companies for attention in Hong Kong. Those include&nbsp;InnoScience&nbsp;(2577.HK), whose shares are up about 20% since their trading debut at the end of last year, as well as&nbsp;Guangdong Tianyu Semiconductor&nbsp;and&nbsp;<a href="https://thebambooworks.com/is-epiworld-banking-on-state-support-in-a-shifting-wafer-market/">Epiworld International</a>, which are both also aiming to list in Hong Kong.

Asia

IPOs

Opinion

Sinking SICC Looks For Lift From Hong Kong IPO

During the last three months, 8 analysts shared their evaluations of Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.25, a high estimate of $8.00, and a low estimate of $2.00. Experiencing a 14.5% decline, the current average is now lower than the previous average price target of $6.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1750075271_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Canaan among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$3.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Kevin Dede</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Canaan. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Canaan compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Canaan's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Canaan's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Canaan analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Canaan</h2>
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
<h3>Key Indicators: Canaan's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Canaan's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 135.89%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Canaan's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -104.42%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Canaan's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -33.84%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Canaan's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -16.81%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Canaan's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.94, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Canaan Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

Even as its troubles refuse to die down, aviation giant Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) remains optimistic about the future and continues to bet on a surge in global air travel over the next two decades.
What Happened: On Sunday, Boeing released its 2025 Commercial Market Outlook, forecasting global demand for commercial aircraft through 2044.
The report, which spans the period from 2025 to 2044, anticipates that the global in-service fleet will nearly double, driven by steady growth in passenger traffic and a rising middle class across emerging markets. It expects demand for 43,600 new commercial airplanes during this period.
See Also: <a href="https://www.benzinga.com/news/social-media/25/06/45941107/mark-cuban-criticizes-bluesky-gets-welcome-back-on-x-by-ceo-yaccarino-welcome-home-to-the-true-global-town-square">Mark Cuban Criticizes Bluesky, Gets Welcome Back On X By CEO Yaccarino: &#8216;Welcome Home To The True Global Town Square&#8217;</a>
A bulk of this demand will be driven by Asia, according to the report, specifically India and China, with single aisle aircraft, such as the 737 Max, leading the way. These planes are essential for supporting the short and medium-haul routes that dominate the aviation markets in these fast-growing regions. 
The report states that the 787 and the upcoming 777X widebody jets will account for just about 7,800 new deliveries, with the rest consisting of single-aisle jets, at 33,285. Dedicated freighter demand is pegged at 955 jets over the forecast period. The cargo segment, which while slowing from its pandemic highs, is still expected to grow at 3.7% annually.
Fleet replacement remains a significant driver of demand in mature markets. Boeing said nearly half of all deliveries globally will replace older, less efficient aircraft.
It&#8217;s worth noting, however, that this marks a decline from the company&#8217;s outlook last year, at 43,975 total deliveries, primarily due to the cut in its wide-body delivery forecasts, as the post-COVID recovery in long-haul travel has been slower, alongside its own delivered capacity that is still 20% below pre-pandemic levels.
Why It Matters: This comes as the company <a href="https://www.benzinga.com/markets/equities/25/06/45940768/boeings-troubled-2000s-from-a-sweetheart-1-1b-deal-before-deadly-air-india-crash-to-stranding-astronauts-at-iss-and-airline-crashes">continues to face scrutiny</a> over multiple crashes, whistleblowers, and multi-billion-dollar fines.
The most recent incident was the <a href="https://www.benzinga.com/markets/equities/25/06/45899174/boeing-dreamliner-carrying-over-200-passengers-crashes-shortly-after-takeoff-near-indias-ahmedabad-ba-stock-falls-over-5-in-thursday-pre-market">crash of a Boeing</a> 787-8 Dreamliner in Ahmedabad, India, last week, just minutes after take-off, resulting in 274 deaths. 
Experts and analysts, however, <a href="https://www.benzinga.com/content/42755161/boeing-4-reasons-it-will-be-the-comeback-story-of-2025">predict a turnaround</a> for the company, with the bad news now firmly behind it, and the company having taken several measures to ensure safety. Leading up to 2025, Boeing also hinted at ramping up the production of its 737 Max aircraft, which has been at the center of this storm.
Price Action: Shares of Boeing were down 1.68% on Friday, trading at $200.32 per share, and are up 0.14% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="145" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/15224532/Screenshot-2025-06-16-at-8.15.17-AM-1024x145.png" alt="" class="wp-image-950083" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/15224532/Screenshot-2025-06-16-at-8.15.17-AM-1024x145.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/15224532/Screenshot-2025-06-16-at-8.15.17-AM-300x42.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/15224532/Screenshot-2025-06-16-at-8.15.17-AM-768x109.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/15224532/Screenshot-2025-06-16-at-8.15.17-AM.png 1526w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Rankings, the stock has a favorable price trend in the short, medium, and long term. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights. 
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45941076/apples-wwdc-2025-unveiling-ios-26-liquid-glass-interface-and-carplay-enhancements">Apple&#8217;s WWDC 2025: Unveiling Ios 26, Liquid Glass Interface And Carplay Enhancements</a></li>
</ul>
Image via Shutterstock

Equities

Markets

Boeing Projects Demand For 43,600 Jets Over Next 20 Years—Asia, Single-Aisle Planes To Lead The Charge

In the preceding three months, 27 analysts have released ratings for Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">4</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $256.85, a high estimate of $400.00, and a low estimate of $169.00. This current average has decreased by 8.73% from the previous average price target of $281.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1750075255_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Coinbase Global by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Trevor Williams</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$260.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$301.00</td>
<td>$252.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$239.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$293.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$209.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$202.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$270.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$276.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$205.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Peter Christiansen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$270.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$276.00</td>
<td>$344.00</td>
</tr>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$260.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Ed Engel</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Sell</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$252.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$290.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$400.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$245.00</td>
<td>-</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$169.00</td>
<td>$328.00</td>
</tr>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$305.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$195.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Coinbase Global. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Coinbase Global compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Coinbase Global's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Coinbase Global's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COIN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Coinbase Global analyst ratings.</a>
<h2>All You Need to Know About Coinbase Global</h2>
Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.
<h3>Understanding the Numbers: Coinbase Global's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Coinbase Global displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 24.23%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Coinbase Global's net margin is impressive, surpassing industry averages. With a net margin of 3.23%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Coinbase Global's ROE excels beyond industry benchmarks, reaching 0.63%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Coinbase Global's ROA excels beyond industry benchmarks, reaching 0.3%. This signifies efficient management of assets and strong financial health.
Debt Management: Coinbase Global's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COIN

27 Analysts Assess Coinbase Global: What You Need To Know

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Graphic Packaging Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>)</h3>
<ul class="wp-block-list">
<li>On May 1, Graphic Packaging Holding reported worse-than-expected first-quarter financial results and cut its FY25 guidance below estimates. Michael Doss, the Company&#8217;s President and CEO said, &#8220;First quarter results fell short of our expectations in a challenging economic and consumer environment. Consumers are redoubling their efforts to find value as food prices continue to rise. Meanwhile, promotional activity is driving mix and brand switching, rather than incremental foot traffic and volume gains. Against that backdrop, we saw a small volume decline in the Americas business, but continued improvement in our International business. Leveraging our growing cost and quality advantage and the strength of our innovation portfolio, we continue to gain market position as we partner with customers in a rapidly changing market.&#8221; The company's stock fell around 10% over the past month and has a 52-week low of $20.86.</li>
<li>RSI Value: 28</li>
<li>GPK Price Action: Shares of Graphic Packaging fell 2.1% to close at $21.10 on Friday.</li>
<li>Edge Stock Ratings: 18.25 Momentum score with Value at 51.14. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/gpk"><img loading="lazy" decoding="async" width="430" height="185" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075547/image-235.png" alt="" class="wp-image-950630" style="width:309px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075547/image-235.png 430w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075547/image-235-300x129.png 300w" sizes="(max-width: 430px) 100vw, 430px" /></a></figure>
<h3 class="wp-block-heading">Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On June 13, Citigroup analyst Patrick Cunningham downgraded Sherwin-Williams from Buy to Neutral and lowered the price target from $405 to $385. The company's stock fell around 8% over the past month and <a href="https://www.benzinga.com/quote/SHW">has a 52-week low</a> of $292.27.</li>
<li>RSI Value: 24.1</li>
<li>SHW Price Action: Shares of Sherwin-Williams fell 5.7% to close at $335.88 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616">SHW stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616"><img loading="lazy" decoding="async" width="931" height="860" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075657/image-236.png" alt="" class="wp-image-950633" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075657/image-236.png 931w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075657/image-236-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075657/image-236-768x709.png 768w" sizes="(max-width: 931px) 100vw, 931px" /></a></figure>
<h3 class="wp-block-heading">Cementos Pacasmayo SAA &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAC#NYSE">CPAC</a>)</h3>
<ul class="wp-block-list">
<li>On April 28, Cementos Pacasmayo posted first-quarter earnings of 16 cents per share. The company's stock fell around 5% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/CPAC">low of $5.10.</a></li>
<li>RSI Value: 28.4</li>
<li>CPAC Ltd Price Action: Shares of CPAC fell 1.4% to close at $5.88 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616">CPAC shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0616"><img loading="lazy" decoding="async" width="880" height="825" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075944/image-237.png" alt="" class="wp-image-950636" style="width:662px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075944/image-237.png 880w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075944/image-237-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16075944/image-237-768x720.png 768w" sizes="(max-width: 880px) 100vw, 880px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Trading Ideas

CPAC

Top 3 Materials Stocks That Could Blast Off This Month

During the last three months, 9 analysts shared their evaluations of Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $68.00, and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 14.84%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750075242_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Intellia Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Andy Chen</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$21.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intellia Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intellia Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Intellia Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Intellia Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NTLA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intellia Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Intellia Therapeutics: A Closer Look</h2>
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
<h3>A Deep Dive into Intellia Therapeutics's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Challenges: Intellia Therapeutics's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -42.54%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Intellia Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -687.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Intellia Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -13.84%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Intellia Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.5%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.15, Intellia Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTLA

Assessing Intellia Therapeutics: Insights From 9 Financial Analysts

Demis Hassabis, chief executive at Google Deepmind, a subsidiary of Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), says the wealth produced by artificial intelligence may one day require a "universal high income" so the gains "are distributed across the economy."
What Happened: In a CNN <a href="https://www.threads.com/@annastewartcnn/post/DKfkWH8MH7z">interview</a>, Hassabis rejected Anthropic CEO Dario Amodei's <a href="https://www.benzinga.com/markets/tech/25/06/45905624/nvidia-ceo-jensen-huang-claps-back-at-anthropics-dario-amodei-says-i-pretty-much-disagree-with-almost-everything-he-said-about-ai-wiping-out-jobs">warning </a>of a "job apocalypse" that could erase half of entry-level office roles within five years. "No, I don't," he said when asked if he shared that view.
"What we know for sure is there's going to be a huge change," comparable to the industrial revolution but compressed into "a shorter period of time, and it may be even bigger." For the next decade, he forecast that generative tools will act as "incredible enhancers for productivity," giving workers almost &#8220;superhuman&#8221; capabilities.
After that, he added, the question becomes how to spread the windfall: "We may need things like universal high income or some way of distributing all the additional productivity that AI will produce."
See also: <a href="https://www.benzinga.com/news/politics/25/06/45945131/trumps-big-beautiful-bill-could-cost-professional-firms-73-billion-lawyers-and-accountants-join-forces-to-resist">Trump&#8217;s &#8216;Big, Beautiful Bill&#8217; Could Cost Professional Firms $73 Billion, Lawyers And Accountants Join Forces To Resist</a>
Why It Matters: The idea pushes the long-running debate over universal basic income into new territory. Hassabis's phrase echoes Elon Musk's prediction of a future "high" guaranteed paycheck for everyone, a view he <a href="https://www.benzinga.com/personal-finance/25/02/43994419/i-dont-think-were-going-to-have-a-choice-elon-musk-predicts-universal-income-will-eventually-be-high-but-fears-people-will-feel">repeated in February</a>.
Other tech leaders, <a href="https://www.benzinga.com/government/24/07/39900023/sam-altman-stands-vindicated-openai-sponsored-no-strings-payment-study-quells-fears-about-misuse-of">including</a> OpenAI's Sam Altman and investor Marc Andreessen, have <a href="https://www.benzinga.com/news/25/02/43498631/wages-will-crash-but-so-will-prices-says-leading-ai-investor-marc-andreessen-on-ais-role-in-ushering-a-productivity-fueled-consumer-boom">promoted</a> broad cash transfers or price-deflation effects to offset wage pressure from automation.
Not everyone is convinced. Trump administration AI adviser David Sacks last week took to X to call such plans "fantasy" and said Congress will never fund them. Economists, <a href="https://www.ft.com/content/27057ff2-e9b6-4630-a6ea-201e0f6d72d9">speaking</a> to the Financial Times, have likewise warned that universal stipends could require unsustainable tax hikes or deliver only token sums that fail to close inequality gaps.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The future of AI has become a Rorschach test where everyone sees what they want. The Left envisions a post-economic order in which people stop working and instead receive government benefits. In other words, everyone on welfare. This is their fantasy; it's not going to happen.
&mdash; David Sacks (@DavidSacks) <a href="https://twitter.com/DavidSacks/status/1929951203015659571?ref_src=twsrc%5Etfw">June 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Hassabis conceded that policy details remain distant while researchers race to make systems like Google's Gemini safer and more reliable. "The most important thing is to make sure it's done responsibly for humanity, given what's at stake," he still argued.
Photo: Mega Pixel/Shutterstock
Read next: <a href="https://www.benzinga.com/markets/equities/25/06/45945153/air-india-boeing-787-8-returns-to-hong-kong-mid-flight-due-to-technical-issue-prompting-fresh-scrutiny-of-airlines-safety-protocols">Air India Boeing 787-8 Returns To Hong Kong Mid-Flight Due To Technical Issue, Prompting Fresh Scrutiny Of Airline&#8217;s Safety Protocols</a>

Tech

GOOG

GOOGL

Google's Demis Hassabis Echoes Elon Musk's Idea Of A Guaranteed Paycheck In The Future, Explains The Need For 'Universal High Income'

Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Bitdeer Technologies, revealing an average target of $17.11, a high estimate of $24.00, and a low estimate of $12.00. This current average has decreased by 3.17% from the previous average price target of $17.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1750075227_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Bitdeer Technologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Nick Giles</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bitdeer Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bitdeer Technologies compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bitdeer Technologies's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Bitdeer Technologies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BTDR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bitdeer Technologies analyst ratings.</a>
<h2>Unveiling the Story Behind Bitdeer Technologies</h2>
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
<h3>Bitdeer Technologies: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Bitdeer Technologies's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -41.32% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bitdeer Technologies's net margin is impressive, surpassing industry averages. With a net margin of 583.89%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bitdeer Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 76.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bitdeer Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 25.94%, the company showcases efficient use of assets and strong financial health.
Debt Management: Bitdeer Technologies's debt-to-equity ratio is below the industry average. With a ratio of 0.38, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTDR

Deep Dive Into Bitdeer Technologies Stock: Analyst Perspectives (9 Ratings)

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $118.38, with a high estimate of $125.00 and a low estimate of $112.00. This upward trend is apparent, with the current average reflecting a 1.66% increase from the previous average price target of $116.45.
<img src="https://www.benzinga.com/files/images/story/2025/1750075216_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Boston Scientific among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$118.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$121.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$117.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$113.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$113.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Boston Scientific. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Boston Scientific's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Boston Scientific's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BSX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boston Scientific analyst ratings.</a>
<h2>About Boston Scientific</h2>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Financial Milestones: Boston Scientific's Journey</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Boston Scientific displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 20.93%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Boston Scientific's net margin excels beyond industry benchmarks, reaching 14.45%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Boston Scientific's ROE excels beyond industry benchmarks, reaching 3.06%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Boston Scientific's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.69% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.53, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Boston Scientific Stock: Analyst Perspectives (13 Ratings)

Last week's positive CPI news briefly pushed the indices market higher, but <a href="https://singaporeforexclub.com/geopolitics-and-forex">geopolitical developments</a> and a threat of yet another war in the Middle East brought the market down.
Amidst the uncertainty, the Swiss franc strengthened further, as expected. However, it is worth noting that this move is not speculative. Swiss bonds are in demand, as 5-year bonds turned negative, for the first time in over 3 years.
This development means that institutions would rather <a href="https://www.benzinga.com/markets/eurozone/25/04/45017967/swiss-franc-soars-as-trump-tariffs-spark-us-volatility">hold the Swiss franc</a> at a 0% interest rate, instead of the Japanese yen, the euro, or any other G10 currency with a notable yield. That fact speaks for the institutional assessment of the fiscal policy risk in the current environment.
The week ahead is marked by significant news, particularly the central bank&#8217;s interest rate decisions. The Swiss National Bank is expected to cut rates to zero, while the Bank of Japan may provide more clarification on the next rate hike.&nbsp;The FED is expected to hold steady at 4.5% and provide updated economic projections, while their counterparts at the Bank of England are also likely to hold at 4.25%.
<h2 class="wp-block-heading">Key News:</h2>
<ul class="wp-block-list">
<li>Tuesday: JPY – Interest Rate, USD – Retail Sales</li>
<li>Wednesday: GBP – CPI, USD – Unemployment Claims, Interest Rate, CAD – Governor Macklem Speech</li>
<li>Thursday: NZD – GDP, AUD – Employment Rate, CHF – Interest Rate, GBP – Interest Rate</li>
<li>Friday: GBP – Retail Sales, JPY – Governor Ueda Speech</li>
</ul>
<h2 class="wp-block-heading">Pairs In Focus</h2>
<h3 class="wp-block-heading">1. AUD/CAD</h3>
After a brief pullback, this pair has established a clear lower high, followed by a correction that has resulted in a lower low. <a href="https://singaporeforexclub.com/forex-price-action">Price action</a> is clearly bearish, and any pullback toward the previous support area around 0.88400-500 is a selling opportunity.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="421" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110301/AUDCAD_2025-06-15_13-28-51-1024x421.png" alt="" class="wp-image-14449" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110301/AUDCAD_2025-06-15_13-28-51-1024x421.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110301/AUDCAD_2025-06-15_13-28-51-300x123.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110301/AUDCAD_2025-06-15_13-28-51-768x316.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110301/AUDCAD_2025-06-15_13-28-51.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
AUD/CAD Daily Chart, Source: TradingView
<h3 class="wp-block-heading">2. GBP/NZD</h3>
This pair made a clear higher low after establishing a higher high in May (surpassing the high from April). Thus, the price action is bullish. Given the odds of the Bank of England holding the rates play into the thesis about the continued strength of the British pound.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="412" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110251/GBPNZD_2025-06-15_13-31-27-1024x412.png" alt="" class="wp-image-14448" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110251/GBPNZD_2025-06-15_13-31-27-1024x412.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110251/GBPNZD_2025-06-15_13-31-27-300x121.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110251/GBPNZD_2025-06-15_13-31-27-768x309.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/16110251/GBPNZD_2025-06-15_13-31-27.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
GBP/NZD Daily Chart, Source: TradingView
The key level to watch is 2.24500, which should provide support, while the short-term target is a previous swing high at 2.27700.
<h3 class="wp-block-heading">&nbsp;Notes:</h3>
<ul class="wp-block-list">
<li>AUD NZD: Established a new 60 pip range, which has to be decisively broken before a new trend could emerge.</li>
<li>AUD CHF: Broke out after confirming a lower high. Price action is bearish and aligned with a stronger Swiss franc.</li>
<li>AUD SGD: It failed to gain bullish traction and fell back into a two-month-long range.</li>
<li>AUD JPY:&nbsp; Failed to gain stronger bullish momentum, but remains above 92.100 support.</li>
<li>CHF JPY:&nbsp; Made a new high after a bullish flag breakout. A short pullback would be unsurprising before trying to capture the long-term target at 180.</li>
<li>CAD JPY: Continues the bullish momentum after rejecting support. An intermediate target remains around 107, about 100 pips higher than last week's close.</li>
<li>EUR JPY: Rallied and hit the liquidity around 106.700, a minor pullback would be unsurprising after such a bullish move.</li>
<li>EUR NZD: Reversed the bearish breakout and turned higher. Price action has tilted bullish, but there is a risk of a prolonged ranging period.</li>
<li>GBP JPY: Overall trend is bullish, but price is struggling to break the key resistance at 196.400.</li>
<li>GBP AUD: This pair made a fakeout lower, before reversing above the key level of&nbsp; 2.08400. It failed to establish a new high for now.</li>
<li>NZD JPY: Ticked higher early in the week before geopolitical developments rallied the yen. Key support to watch below is around 85.500.</li>
</ul>
Disclaimer: Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. Singapore Forex Club is not responsible for any financial decisions based on this article's contents. We provide research and promote&nbsp;<a href="https://singaporeforexclub.com/how-to-start-trading-forex-in-singapore" target="_blank" rel="noreferrer noopener">forex trading in Singapore</a>, and readers may use this data for information and educational purposes only.

Forex

Bond Market Confirms Swiss Franc Strength

Barclays analyst Saket Kalia initiates coverage on Hinge Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) with a Overweight rating and announces Price Target of $43.

HNGE

Barclays Initiates Coverage On Hinge Health with Overweight Rating, Announces Price Target of $43

HC Wainwright &amp; Co. analyst Mitchell Kapoor downgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Sell and lowers the price target from $40 to $10.

Downgrades

SRPT

HC Wainwright & Co. Downgrades Sarepta Therapeutics to Sell, Lowers Price Target to $10

Leerink Partners analyst Mike Kratky initiates coverage on Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Outperform rating and announces Price Target of $118.

Leerink Partners Initiates Coverage On Boston Scientific with Outperform Rating, Announces Price Target of $118

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and maintains $30 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target

Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) on Sunday revealed the first clinical data from two studies evaluating the safety, tolerability, and efficacy of INCA033989 for mutant calreticulin (mutCALR)-expressing <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">myeloproliferative neoplasms (MPNs)</a>.
MPNs are&nbsp;a group of rare blood cancers where the bone marrow produces too many blood cells (red blood cells, white blood cells, or platelets).
These data, featured at the European Hematology Association 2025 (EHA2025), focus on the dose escalation portion of the&nbsp;studies in patients with high risk essential thrombocythemia (ET) who are resistant/intolerant to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45940099/positive-late-breaking-data-for-incytes-first-in-class-mutcalr-targeted-therapy-inca033989-in-esse" rel="noreferrer noopener">prior cytoreductive therapy</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44356786/incytes-new-treatment-for-chronic-skin-disease-shows-promising-results-in-latest-clinical-trials-stock-falls" target="_blank" rel="noreferrer noopener">Incyte&#8217;s New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls</a>
The studies evaluated the safety and efficacy of INCA033989 in patients with ET as measured by hematologic response and reduction in mutCALR variant allele frequency (VAF).
As of April 4, 2025, results showed rapid and durable normalization of platelet counts across all dose levels, with a trend toward improved responses in higher doses (&gt;400 mg) in patients with ET treated with INCA033989.
Eighty-six percent of patients at doses 400 mg and above achieved a complete or partial hematologic response, with the majority (82%) achieving a complete response.
Eighty-nine percent of evaluable patients (34/38) showed a reduction in mutCALR VAF from baseline. A partial molecular response (>50% VAF reduction) was observed in 21% of evaluable patients (8/38) after only three cycles of treatment.
An exploratory study using single-cell DNA (scDNA) sequencing showed that INCA033989 directly targets and reduces cells carrying mutCALR. This reduction was seen in early blood-forming (CD34-positive) cells and cells in the myeloid-erythroid (ME) lineage.
At the same time, there was an increase in healthy (wild-type CALR) cells, suggesting that the treatment supports the return of normal blood production.
Bone marrow biopsies further confirmed these effects, showing fewer megakaryocytes with mutCALR protein and a notable increase in megakaryocytes without mutCALR protein.
The results (N=49) showed that INCA033989 was well tolerated across all dose cohorts (24 to 2,500 mg), with no dose-limiting toxicities observed.
Additional data from the INCA033989 study in patients with myelofibrosis will be submitted for presentation at a future medical meeting. Discussions with regulatory authorities are planned with the goal to initiate a Phase 3 study by early 2026.
William Blair views the INCA33989 update as promising, with strong initial efficacy reported. However, some questions remain around dosing differences between type 1 and type 2 mutCALR patients and the best setting for the therapy in ET patients (post-hydroxyurea, in combination, or head-to-head).
Analyst Matt Phipps noted that investors have debated the read-through of the ET data to the potential of INCA33989 in MF, where results as a monotherapy and in combination with Jakafi are expected later this year. The VAF reductions are encouraging and likely to have read-through to additional indications, he mentioned in a report.
Price Action: INCY stock is trading higher by 6.82% to $72.37 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45755748/johnson-johnson-highlights-multiple-blood-cancer-trial-data-at-asco-presentation" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation</a></li>
</ul>
Photo via Shutterstock

Comments

Defiance Daily Target 2X Long AVGO ETF

뉴스

에 대한 최신 뉴스 Defiance Daily Target 2X Long AVGO ETF (NASDAQ:AVGX)

뉴스

파트너 / 기고자

벤징가 글로벌